# GLP-1 medicines and “food noise”: what studies measure

Less hunger and fewer food thoughts are related experiences. Appetite studies help explain them, while showing why the effect can change over time.

Canonical: https://velri.co/blog/glp1-food-noise-quiet-mechanism-first-timer
Publisher: Velri (https://velri.co/about)
Published: 2026-07-05
Updated: 2026-09-30
Editorial policy: https://velri.co/editorial-policy

People often use “food noise” to describe recurring thoughts about eating, cravings or the mental effort of deciding whether to eat. Researchers usually measure more specific experiences, such as hunger, food preoccupation, cravings and control of eating. [1][2]

Semaglutide and tirzepatide act on receptors involved in appetite regulation and can reduce calorie intake. That provides a biological explanation for why eating may feel different during treatment. [3][4]

## What have studies found?

A small randomized crossover study of semaglutide in adults with obesity found less hunger and fewer cravings, better control of eating and lower measured food intake compared with placebo. Nausea ratings were similar between treatments, so the appetite findings were not simply a report that participants felt too sick to eat. [1]

A later 60-week randomized study in 120 adults measured both laboratory food intake and subjective appetite. Semaglutide reduced food intake compared with placebo at weeks 20, 40 and 60. Some reported appetite benefits, including less food preoccupation, were clearer early in treatment and were not significantly different between groups at the later assessments. [2]

Those findings explain an important distinction: how hungry someone feels and how much they eat can change differently over time. [2]

## Hunger can still be present

The trials assessed average changes in particular measures. They did not establish complete absence of hunger or food thoughts as a requirement for treatment benefit. [1][2]

The useful comparison is with your own eating experience over time.

## What is worth noticing?

A useful description names the change: fewer cravings, less preoccupation between meals, different portions, or more comfortable control over eating. It also separates those experiences from nausea or an inability to eat enough, which belong in a side-effect review. [1][3][4]

Follow-up can consider both the changes you value and any difficulty eating enough. [2][3][4]

## Sources
[1] Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. (2017). https://pubmed.ncbi.nlm.nih.gov/28266779/
[2] Short- and long-term effects of semaglutide 2.4 mg on energy intake, appetite, and food reward: a 60-week, double-blind randomized controlled trial. (2026). https://pubmed.ncbi.nlm.nih.gov/42323166/
[3] DailyMed - WEGOVY- semaglutide injection, solution
WEGOVY- semaglutide tablet (2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
[4] DailyMed - ZEPBOUND- tirzepatide injection, solution
ZEPBOUND- tirzepatide injection, solution
ZEPBOUND KWIKPEN- tirzepatide injection, solution (2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b

## About this information
General health information, not personal medical advice, diagnosis or treatment. A prescription is required and is never guaranteed.
Velri is a brand operated by Velri Management LLC, a Nevada limited liability company. Velri is a non-clinical technology and administrative services company. Velri does not provide medical advice, diagnosis, treatment, or pharmacy services, and does not direct the clinical judgment of any provider.
All medical consultations and prescriptions are provided directly by independent provider groups (Online Medical Care, P.C.; TMD of Kansas, P.A.; TMD of Texas, P.A.; and TMD of CA, PC), by a provider licensed in your state. Velri does not employ providers. A prescription is issued only if a provider determines it is clinically appropriate in their independent medical judgment.
All prescription products are dispensed by independent, licensed pharmacies. Velri does not own, operate, or control any pharmacy and does not dispense medication. You may opt out of using a given provider group or pharmacy at any time.
Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
Velri is cash-pay. We do not bill Medicare, Medicaid, or commercial insurance. Refunds and order problems are addressed in the Terms of Use; your rights under applicable law are not limited. State availability and clinical eligibility apply.
Velri and telehealth are not for medical emergencies. If you are experiencing an emergency, call 911.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Care is available to eligible adults 18 and older in 47 states and D.C., United States only.
Notice of Privacy Practices: https://velri.co/privacy/notice-of-privacy-practices
Terms: https://velri.co/legal/terms
Provider group or pharmacy opt-out help: https://velri.co/contact and https://velri.co/standards#trust-support